Item 7.01. Regulation FD Disclosure.

On December 12, 2022, Imago BioSciences, Inc. ("Imago") announced the presentation of positive data from ongoing Phase 2 study of Bomedemstat in Essential Thrombocythemia (ET) and in advanced myelofibrosis (MF), respectively, at the 64th American Society of Hematology Annual Meeting and Exposition (ASH). Copies of the press releases Imago issued announcing the positive data are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated by reference into this Item 7.01.

The information in Item 7.01, including Exhibit 99.1 and Exhibit 99.2, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits.

Exhibit     Description

99.1          Press Release dated December 12, 2022 (ET)

99.2          Press Release dated December 12, 2022 (MF)

104         Cover Page Interactive Data File (formatted as Inline XBRL and
            contained in Exhibit 101)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses